What to Know for National Influenza Vaccination Week 2020
December 03, 2020 06:00pm
By Contemporary Clinic Editorial Staff
The FDA is hosting a 2-day advisory committee meeting to address new ways that the availability of naloxone (Narcan and Evzio) can be increased.
The FDA is hosting a 2-day advisory committee meeting to address new ways that the availability ofnaloxone(Narcan and Evzio) can be increased. The drug is a critical tool for individuals, families, first responders, and communities to help reduce deaths from opioid overdose, according to the FDA Commissioner Scott Gottlieb, MD.
In a prepared statement, Gottlieb said there is an urgency in making naloxone more accessible. He noted that the number of overdose deaths from prescription and illicit opioids doubled from 21,089 in 2010 to 42,249 in 2016.
During the planned meeting, to be held in December in Silver Spring, MD, agency officials will consult with external advisors from the FDA's’s Anesthetic and Analgesic Drug Products and the Drug Safety and Risk Management Advisory Committees to consider various options that would help naloxone become more accessible. According to Gottlieb's statement, these advisors will assist the agency in weighing logistical, economic, and harm reduction aspects of different strategies. Meeting participants will also consider whether naloxone should be co-prescribed with all or some opioid prescriptions to reduce the risk of overdose death.
“There is the potential for significant costs and burdens that may be associated with naloxone co-prescribing. These include the direct economic costs to consumers and health systems. They also include practical considerations such as the need for manufacturing volume growth for naloxone, and the risk of drug shortages of this product that could come from a sudden spike in prescribing,” said Gottlieb, in his statement.
FDA officials and advisors are expected to evaluate these and other considerations, as part of their effort to consider any potential challenges to wider co-prescribing of naloxone for all or some prescription opioid patients. According to Gottlieb, meeting participants plan to discuss the potential development of over-the-counter naloxone.
"Another topic we plan to discuss is the work that many organizations and local municipalities across the U.S. have done to develop programs for making naloxone available in the community. We hope to glean insight from these efforts to further our own goals at expanding naloxone availability," said Gottlieb, in his statement.
Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to advance new ways to increase the availability of naloxone as one means for reducing opioid overdose deaths [news release]. Silver Spring, MD; October 23, 2018: FDA website. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm624053.htm. Accessed October 23, 2018.